Christopher Nevala-Plagemann
( out of 81 reviews )

Christopher Nevala-Plagemann, MD, MSCI

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-585-0250

Sugar House Health Center

Salt Lake City
801-581-2000

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 81 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 25, 2024
    SUGAR HOUSE HEALTH CENTER

    this is the Dr you'd want if you ever needed chemo

    July 16, 2024
    HUNTSMAN CANCER CENTER

    Dr. Nevala treated me very well. He listened, answered all my questions and explained the option for my cancer. He was very positive and I left his office feeling very optimistic about my future.

    July 05, 2024
    SUGAR HOUSE HEALTH CENTER

    Very compassionate and caring

    May 29, 2024
    SUGAR HOUSE HEALTH CENTER

    Excellent doc - checks all the boxes when it comes to patient care and communication. Amazingly compassionate, obviously very knowledgeable, and extremely patient. 10 out of 10 - no question in his ability or desire to help patients who need very involved care. .

    May 24, 2024
    SUGAR HOUSE HEALTH CENTER

    Great follow-up. Explained options clearly. Appreciate the time he took.

    May 01, 2024
    SUGAR HOUSE HEALTH CENTER

    Amazing doctor - kind, compassionate, knowledgeable, and articulate. He is very patient and he and his team manage to be very accessible as well.. every time we've met we've left the appointment with what we need and a clear path forward.

    April 26, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Chris is the best!!!

    April 04, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Nevala and his team seem to be invested in my care. He answered my questions, he was direct without being harsh or making me worry unnecessarily. He had already reviewed my case before my appointment and showed me what the test results meant for my diagnosis. He had a plan and it was easy to understand.

    March 28, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Nevala is a caring intelligent guy who takes the time to explain things thoroughly and answer all my questions

    See More Patient Comments

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah School of Medicine M.S.
    Hematology/Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Medicine - University of Minnesota Medical School M.D.
    Undergraduate Biology - Luther College B.A.

    Selected Publications

    Journal Article

    1. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol, 14(6), 2637-2643. (Read full article)
    2. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. (Read full article)
    3. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. (Read full article)
    4. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. (Read full article)
    5. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 268-275. (Read full article)
    6. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. (Read full article)
    7. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. (Read full article)
    8. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. (Read full article)
    9. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. (Read full article)
    10. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123. (Read full article)
    11. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. (Read full article)
    12. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. (Read full article)
    13. Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795. (Read full article)

    Review

    1. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. [Review]. Ther Adv Med Oncol, 13, 17588359211045861. (Read full article)
    2. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Metastatic Pancreatic Cancer. [Review]. Pancreas, 50(6), 773-787. (Read full article)
    3. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. [Review]. Nat Rev Clin Oncol, 17(2), 108-123. (Read full article)

    Case Report

    1. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. (Read full article)
    2. Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493. (Read full article)